Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

574
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
574
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

462
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
462

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026
Same author

Decoding splicing variants in high-throughput sequencing: a functional validation approach integrating deep learning tools.

European journal of human genetics : EJHG·2026
Same author

Functional and Molecular Characterization of Novel <i>GDF2 (BMP9</i>) and <i>BMP10</i> Variants From the French PAH and HHT Cohorts.

Circulation. Genomic and precision medicine·2026
Same author

Detection of Patent Foramen Ovale: Transcranial Doppler and Echocardiography Are Not Equivalent to Define a Large Shunt.

Journal of clinical ultrasound : JCU·2026
Same author

Cardiac Radiation Dose and Subclinical Coronary Artery Disease Progression after Breast Cancer Radiotherapy: 2-year Cardiac CT Results from the EARLY-HEART Study.

Radiology. Cardiothoracic imaging·2026
Same author

Quantification of Tricuspid Valve Regurgitation With 2D and 4D-Flow MRI: Comparison of Different Methods in Adult Patients With Ebstein's Anomaly.

Journal of magnetic resonance imaging : JMRI·2026

相关实验视频

Updated: May 29, 2025

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
12:00

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

19.1K

艾勒斯- 丹洛斯血管综合征患者治疗伊尔贝沙坦的有效性

Xavier Jeunemaitre1,2, Elie Mousseaux1,3, Michael Frank4

  • 1PARCC (X.J., E.M., P.B., T.M., G.C.), Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Cité, France.

Circulation
|February 5, 2025
PubMed
概括

艾勒斯- 丹洛斯综合征患者服用伊尔贝萨坦可显著减少动脉事件. 这项研究表明,在这种罕见的遗传性疾病中,添加血管激素II受体抑制剂是有益的.

关键词:
艾勒斯 - 丹洛斯综合征,类型IV血管素受体对抗剂其他药物原蛋白计算机断层扫描血管学

更多相关视频

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K
Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
08:05

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

3.9K

相关实验视频

Last Updated: May 29, 2025

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro
12:00

Extraction and Purification of Polyphenols from Freeze-dried Berry Powder for the Treatment of Vascular Smooth Muscle Cells In Vitro

Published on: July 5, 2017

19.1K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.7K
Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
08:05

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

3.9K

科学领域:

  • 心血管医学
  • 遗传学
  • 药理学

背景情况:

  • 血管埃勒斯-丹洛斯综合征 (vEDS) 是一种罕见的遗传疾病,影响III型原.
  • 这会显著增加动脉并发症和死亡的风险.
  • 目前的治疗方法,包括塞利普罗洛尔,缺乏对疗效的受控试验数据.

研究的目的:

  • 评估艾伯沙坦 (一种血管素II受体阻断剂) 的成年患者的疗效和安全性.
  • 评估将伊尔贝萨坦添加到稳定的塞利普罗罗罗尔治疗中的影响.
  • 在vEDS患者中研究血管事件的减少和动脉病变的进展.

主要方法:

  • 一个多中心,随机,安慰剂对照试验.
  • 29名患者接受了irbesartan (150- 300毫克/ 天),28名患者接受了安慰剂2年.
  • 主要结局:通过成像测试的致命/非致命动脉事件或新的/恶化的动脉病变的组合.

主要成果:

  • 伊尔贝萨坦使综合初级结局降低了58% (HR为0.42,P<0.05).
  • 艾尔贝萨坦治疗时,动脉复发事件的风险显著降低 (RR 0.37,P=0. 002).
  • 伊布沙坦降低了5. 4 mm Hg (P< 0. 001) 的静脉压;在11例病例中出现了低血压.

结论:

  • 伊尔贝萨坦显著降低了患者有症状和无症状动脉事件的风险.
  • 添加伊尔贝萨坦与塞利普罗洛尔治疗对控制静脉风险有好处.
  • 在这种患者群体中,伊尔贝萨坦具有良好的风险益处概况.